Core Insights - Immunome, Inc. (IMNM) shares increased by 6% to close at $9.3, driven by higher trading volume compared to typical sessions, contrasting with a 0.1% gain over the past four weeks [1][2] Company Performance - The rise in stock price is linked to growing investor optimism regarding the development of varegacestat, which is in late-stage clinical studies for treating desmoid tumors, alongside other early-stage cancer therapies [2] - The company is projected to report a quarterly loss of $0.52 per share, reflecting a year-over-year decline of 6.1%, with expected revenues of $2.47 million, an increase of 4.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 1.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Immunome is categorized under the Zacks Medical - Biomedical and Genetics industry, where Nurix Therapeutics, Inc. (NRIX) also operates, closing 2.2% lower at $11.39, with a 9.5% return over the past month [5] - Nurix Therapeutics has an unchanged consensus EPS estimate of -$0.72 for the upcoming report, representing a year-over-year change of -1.4% [6]

Core Viewpoint - Darling Ingredients (DAR) has shown a significant price increase of 23.2% over the past four weeks, with a mean price target of $52.69 indicating a potential upside of 38.9% from the current price of $37.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $18.88, suggesting variability in analyst predictions. The lowest estimate is $34.00 (10.4% decline), while the highest is $110.00 (189.9% increase) [2] - Analysts' price targets can often mislead investors, as empirical research indicates that these targets rarely reflect actual stock price movements [7][10] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about DAR's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.4%, with one estimate moving higher and no negative revisions [12] - DAR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a solid potential upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of DAR's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Radius Recycling reported a quarterly loss of $0.39 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.87, representing an earnings surprise of +55.17% [1] - The company posted revenues of $726.99 million for the quarter ended May 2025, exceeding the Zacks Consensus Estimate by 7.38% and showing an increase from $673.92 million year-over-year [2] - Radius Recycling shares have increased approximately 95.1% since the beginning of the year, outperforming the S&P 500's gain of 5.5% [3] Group 2 - The earnings outlook for Radius Recycling is mixed, with the current consensus EPS estimate for the coming quarter at -$0.56 on revenues of $663 million, and -$3.84 on revenues of $2.62 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Waste Removal Services sector is currently in the bottom 30% of over 250 Zacks industries, which may impact the stock's performance [8]

Market Overview - The first half of 2025 experienced increased volatility and uncertainty due to President Trump's tariffs and a faster-than-expected cooling of inflation, leading to market recovery [1] - Recent months have shown favorable market conditions with easing trade tensions and a reduction in the Middle East crisis [1] Stock Performance and Recommendations - Optimism regarding artificial intelligence is expected to continue supporting stock prices, particularly in technology sectors [2] - Cooling inflation raises expectations for potential rate cuts starting in September 2025, contributing to a positive market outlook [2] - Stocks such as Cracker Barrel Old Country Store (CBRL), BGSF, ArcBest Corporation (ARCB), Cardinal Health (CAH), and AutoNation (AN) are recommended for monitoring as the second half of 2025 begins [2][6] Screening Strategy - A screening strategy has been developed to identify stocks based on improving broker recommendations and upward revisions in earnings estimates over the past four weeks [3] - The price/sales ratio is included as a valuation metric, focusing on companies with strong top-line performance [3] Screening Criteria - The top 75 companies with net upgrades in broker ratings over the last four weeks are identified [4] - The top 10 stocks with the highest percentage change in earnings estimates for the upcoming quarter are highlighted [4] - Companies in the bottom 10% of price-to-sales ratios are included for better valuation [4] Company Highlights - Cracker Barrel is focusing on menu innovation and pricing strategies to drive growth, introducing new offerings to attract customers [5] - BGSF has seen a 25% increase in shares over the past month and has a Zacks Rank 1, with earnings estimates rising over 300% in the last 60 days [7] - ArcBest is improving productivity and service quality, expecting a 52.1% increase in earnings per share for 2026 compared to 2025 [8] - Cardinal Health is undergoing strategic improvements to revitalize its business model, with its Medical segment expected to drive growth [9][10] - AutoNation's diversified product portfolio and strategic acquisitions support its market position, currently holding a Zacks Rank 3 [11]

Core Viewpoint - Novavax has experienced a significant decline in stock performance, with a return of -10.9% over the past month, contrasting with the S&P 500's +5.2% and the Zacks Medical - Biomedical and Genetics industry's +0.9% [2] Earnings Estimates - For the current quarter, Novavax is projected to report a loss of $0.12 per share, reflecting a -112.1% change year-over-year, with the consensus earnings estimate for the fiscal year at $2.65, indicating a +315.5% change [5][6] - The consensus earnings estimate for the next fiscal year is $0.4, which represents a -84.8% change from the previous year [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $130.5 million, indicating a year-over-year decline of -68.6%. For the current fiscal year, the estimate is $1.07 billion (+56.8%), while for the next fiscal year, it is $516.45 million (-51.7%) [11] Last Reported Results and Surprise History - In the last reported quarter, Novavax achieved revenues of $666.66 million, a +610.3% year-over-year increase, with an EPS of $2.93 compared to -$1.05 a year ago. The revenue exceeded the Zacks Consensus Estimate by +215.04%, and the EPS surprise was +312.68% [12][13] Valuation - Novavax is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers, which suggests potential undervaluation [17]

First United Corporation (FUNC) shares ended the last trading session 6.1% higher at $31.01. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.8% loss over the past four weeks.First United became a part of the Russell 2500 Index, a mid-cap benchmark, effective yesterday. The bank’s inclusion signals its market cap growth and compliance with index criteria. This move boosted short-term liquidity and trading volume a ...

分组1 - MSC Industrial reported quarterly earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $1.03 per share, but down from $1.33 per share a year ago, representing an earnings surprise of +4.85% [1] - The company posted revenues of $971.15 million for the quarter, surpassing the Zacks Consensus Estimate by 0.10%, but down from $979.35 million year-over-year [2] - MSC Industrial has outperformed the S&P 500 with a share price increase of about 13.8% since the beginning of the year, compared to the S&P 500's gain of 5.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.93 on revenues of $946.5 million, and for the current fiscal year, it is $3.55 on revenues of $3.74 billion [7] - The Industrial Services industry, to which MSC Industrial belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8]

Company Performance - MercadoLibre (MELI) closed at $2,613.63, reflecting a +2.09% increase from the previous day, outperforming the S&P 500's gain of 0.52% [1] - Over the past month, the stock has decreased by 0.13%, underperforming the Retail-Wholesale sector's gain of 2.65% and the S&P 500's gain of 4.27% [1] Earnings Forecast - The upcoming earnings report is expected to show an EPS of $12.01, representing a 14.6% increase from the same quarter last year [2] - Projected net sales are estimated at $6.52 billion, which is a 28.57% increase from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are forecasted at $47.75 per share, indicating a +26.69% change from the previous year, with revenue expected to reach $27.35 billion, reflecting a +31.66% increase [3] - Recent analyst estimate revisions suggest a favorable outlook on the company's business health and profitability [3] Analyst Ratings and Valuation - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently rates MercadoLibre at 3 (Hold) [5] - The Forward P/E ratio for MercadoLibre is 53.62, significantly higher than the industry average of 24.95, with a PEG ratio of 1.52 compared to the industry average of 1.41 [6] Industry Context - The Internet - Commerce industry, part of the Retail-Wholesale sector, holds a Zacks Industry Rank of 58, placing it in the top 24% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]

Progress Software (PRGS) came out with quarterly earnings of $1.4 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.69%. A quarter ago, it was expected that this business software maker would post earnings of $1.04 per share when it actually produced earnings of $1.31, delivering a surprise of +25.96%.Over the last four quart ...

Core Insights - Bumble Inc. (BMBL) shows potential as a strong portfolio addition due to significant revisions in earnings estimates [1] - The upward trend in earnings estimate revisions reflects growing analyst optimism, which is likely to influence stock price positively [2] Earnings Estimate Revisions - Current-quarter earnings estimate is $0.31 per share, representing a +40.91% change from the previous year [5] - The Zacks Consensus Estimate for the current quarter has increased by 7.42% over the last 30 days, with two estimates raised and no negative revisions [5] - For the full year, the earnings estimate is $0.91 per share, indicating a +119.74% change from the year-ago figure [6] - The consensus estimate for the current year has risen by 6.76% due to two upward revisions and no negative changes [7] Zacks Rank and Performance - Bumble currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions and potential for outperformance [8] - Historically, Zacks 1 (Strong Buy) and 2 (Buy) stocks have significantly outperformed the S&P 500 [8] Investment Outlook - Strong estimate revisions have led to a 14.8% increase in Bumble's stock price over the past four weeks, suggesting further upside potential [9] - Investors may consider adding Bumble to their portfolios based on the positive earnings outlook [9]